Reply to Rizzo et al.

Código QR

Reply to Rizzo et al.

n.a.

Guardado en:

Detalles Bibliográficos
Autores principales:	Arndt Vogel, Javier Sanchez Alvarez, Monica Daigl, Philippe Merle
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f7134c1df3c14be7b8718d0a13b8dda9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter to the editor from Pant et al
por: Aung Naing, et al.
Publicado: (2021)

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
por: Vogel VG
Publicado: (2011)

Reply to Stummer, W.; Thomas, C. Comment on “Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)—Experience at Two Specialized Centers. <i>Cancers</i> 2021, <i>13</i>, 2540”
por: Arthur Hosmann, et al.
Publicado: (2021)

Pembrolizumab-induced massive hypereosinophilia associated with mononeuritis multiplex, brain microvascular lesions and intestinal eosinophilic infiltration in a melanoma patient
por: Kim Dao, et al.
Publicado: (2021)

Artificial intelligence for the next generation of precision oncology
por: Pedro J. Ballester, et al.
Publicado: (2021)

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group
por: Marion Maetens, et al.
Publicado: (2017)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli Atrash, et al.
Publicado: (2021)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Willard Wong, et al.
Publicado: (2021)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: María Gion, et al.
Publicado: (2021)

Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. <i>Cancers</i> 2020, <i>12</i>, 94
por: Mei-Ren Pan, et al.
Publicado: (2021)

How I faced my prostate cancer: a molecular biologist’s perspective
por: Monica Zuradelli, et al.
Publicado: (2021)

Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases
por: Yingmei Li, et al.
Publicado: (2021)

Correction: Welter et al. Characteristics of Nephroblastoma/Nephroblastomatosis in Children with a Clinically Reported Underlying Malformation or Cancer Predisposition Syndrome. <i>Cancers</i> 2021, <i>13</i>, 5016
por: Nils Welter, et al.
Publicado: (2021)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Christopher Alvarez-Breckenridge, et al.
Publicado: (2017)

Nobody dares stopping clinical research, not even COVID-19
por: Andrea Malfettone, et al.
Publicado: (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Jean Galtier, et al.
Publicado: (2021)

Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations
por: Neil M. Iyengar, et al.
Publicado: (2021)

Comment on Kronenfeld et al. Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. <i>Cancers</i> 2021, <i>13</i>, 3814
por: Markus Notter, et al.
Publicado: (2021)

Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
por: Adrián Sánchez-Fdez, et al.
Publicado: (2021)

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
por: Ali Bohlok, et al.
Publicado: (2020)

Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
por: Alberto Carmona-Bayonas, et al.
Publicado: (2021)

Correction: Sioud et al. Evaluation of In Vitro Phototoxicity of a Minibody-IR700 Conjugate Using Monolayer and Multicellular Tumor Spheroid Models. <i>Cancers</i> 2021, <i>13</i>, 3356
por: Mouldy Sioud, et al.
Publicado: (2021)

Correction: Kaushal et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. <i>Cancers</i> 2021, <i>13</i>, 3105
por: Jyoti B. Kaushal, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Shahram Salek-Ardakani, et al.
Publicado: (2021)

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
por: Carlos Fernández de Larrea, et al.
Publicado: (2021)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
por: Linda T. Vahdat, et al.
Publicado: (2021)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Tomás Pascual, et al.
Publicado: (2021)

Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma
por: Raul Caso, et al.
Publicado: (2021)

Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial
por: Gilles Houvenaeghel, et al.
Publicado: (2021)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: Leticia De Mattos-Arruda, et al.
Publicado: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Xavier Pivot, et al.
Publicado: (2017)

Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America
por: Josef S. Herzog, et al.
Publicado: (2021)

Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia
por: Mayumi Sugita, et al.
Publicado: (2021)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: David Goldstein, et al.
Publicado: (2021)

Comment on Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)—Experience at Two Specialized Centers. <i>Cancers</i> 2021, <i>13</i>, 2540
por: Walter Stummer, et al.
Publicado: (2021)

Case Reports in Oncology
Publicado: (2009)

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
por: Laia Garrigós, et al.
Publicado: (2021)

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
por: Khalid El Bairi, et al.
Publicado: (2021)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Enriqueta Felip, et al.
Publicado: (2021)

Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis
por: Ke Wang, et al.
Publicado: (2021)